ANI Pharmaceuticals ANIP Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $78.34M+523% | -$18.52M-199% | $18.78M+139% | -$47.9M-12.4% | ||
| $91.42M+35.0% | $67.73M+13.3% | $59.79M+0.2% | $59.65M+26.2% | ||
| $37.93M+29.3% | $29.34M+42.1% | $20.65M+41.5% | $14.6M+39.2% | ||
| $185.23M+189% | $64.02M-46.2% | $118.96M— | —— | ||
| $13.84M-14.8% | $16.24M+83.1% | $8.87M-0.1% | $8.88M+247% | ||
| -$34.32M+91.5% | -$404.72M-2,086% | -$18.51M-17.6% | -$15.74M+85.1% | ||
| $1.16M-28.8% | $1.63M0.0% | $1.63M0.0% | $1.63M+755% | ||
| $12.21M+11.4% | $10.96M+120% | $4.99M+155% | $1.96M+120% | ||
| $0-100% | $292.5M— | $0— | $0-100% | ||
| —— | $269.85M— | —— | -$5.13M-103% | ||
| $140.73M+285% | -$76.23M-145% | $167.89M+422% | -$52.07M— | ||
| $171.39M+259% | $47.78M-56.6% | $110.09M+367% | -$41.23M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does ANI Pharmaceuticals's cash flow data come from?
- Every line is extracted from ANI Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.